| Name | Aldoxorubicin hydrochloride |
| Description | Aldoxorubicin hydrochloride is an albumin-binding prodrug of Doxorubicin, a DNA topoisomerase II inhibitor. Aldoxorubicin hydrochloride is released from albumin under acidic conditions. Aldoxorubicin hydrochloride exhibits potent antitumor activities in various cancer cell lines and in murine tumor models. |
| In vitro | Aldoxorubicin hydrochloride (0.27 to 2.16 μM) inhibits formation of blood vessel and reduces growth of multiple myeloma cell in a pH-dependent fashion[1]. |
| In vivo | Aldoxorubicin hydrochloride (10.8 mg/kg, i.v.) significantly reduces tumor volumes and IgG levels by day 28, showing high tolerability with a 90% survival rate in mice with LAGκ-1A tumors [1]. It demonstrates a favorable safety profile at doses up to 260 mg/mL doxorubicin equivalents, effectively inducing tumor regression in breast cancer, small cell lung cancer, and sarcoma during a phase I study [2]. Additionally, it outperforms doxorubicin in murine renal cell carcinoma and breast carcinoma xenograft models [3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 127.5 mg/mL (161.96 mM), Sonication is recommended.
|
| Keywords | topoisomerase II | Aldoxorubicin Hydrochloride | 1361644-26-9 Free base | 1361644-26-9 |
| Inhibitors Related | Ciprofloxacin hydrochloride monohydrate | Levofloxacin hydrochloride | Norfloxacin | Anthraquinone | Methotrexate disodium | Prulifloxacin | 1,4-Naphthoquinone | Ofloxacin | Levofloxacin | Dexamethasone | 3-Hydroxypyridine | Etoposide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
